Share-Based Compensation (Tables)

12 Months Ended

Oct. 31, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Assumptions Used to Determine Grant-Date Fair Value of Stock Options

The assumptions that the Company used to determine the grant-date fair value of stock options during the years ended October 31, 2024 and 2023, were as follows:

	Year ended October 31,
	2024				2023
Expected term (in years)		5.51-6.08			5.2 – 6.08
Expected volatility		78.24-82.33%			79.92 – 81.48%
Risk-free interest rate		1.78-4.66%			3.56 – 4.35%
Expected dividend yield			—			—
Fair value of common shares and exercise    price of options (CAD)	$	N/A		$	2.11 – 12.36
Fair value of common shares and exercise    price of options (USD)	$	4.73-12.60		$	1.52 – 8.93

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity:

	Number of Shares			Weighted- Average Exercise Price (USD)		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding as of October 31, 2023		2,706,941		$	2.40		8.1	$	52,192
Granted		3,591,200			10.18
Exercised		(116,752	)		0.97
Forfeited or expired		(146,877	)		6.71
Outstanding as of October 31, 2024		6,034,512		$	6.88		7.4	$	17,809
Options vested and exercisable as of October 31, 2024		2,497,082		$	2.32		4.4	$	16,311
Options unvested as of October 31, 2024		3,537,430		$	10.10		9.6	$	1,498

Summary of Share-based Compensation Expense

Share-based compensation expense included in the Company’s consolidated statements of operations and comprehensive loss was as follows:

	Year Ended October 31,
	2024		2023
Research and development	$	1,794	$	780
General and administrative		3,530		2,670
Total share-based compensation expense	$	5,324	$	3,450